Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8734MR)

This product GTTS-WQ8734MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8734MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12550MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ12007MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ8108MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ5223MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ9289MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ109MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ4441MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ11731MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW